March 01, 2010 – The United States Patent and Trademark Office (USPTO) granted Epinex Diagnostics the patent for its primary technology, the G1A™ Rapid Diabetes Monitoring Index Test. The patent (US7659107B2) is for the first ever rapid glycated albumin test and instrument, which could redefine the way diabetes is monitored for over 250 million diabetics worldwide. The G1A™ test provides a monthly diabetes-monitoring index by measuring damage caused by excess sugar to albumin, the most abundant serum protein. Albumin is an ideal monthly marker as it is replaced in the body every 2-3 weeks. Using only a pinprick of blood, the test will simultaneously and rapidly measure glycated albumin and total albumin. Researchers at the Wake Forest University School of Medicine have described glycated albumin as a “more robust” and “more accurate” indicator of long-term glycemic control... [PDF] Epinex Diagnostics' Press Release -
